Prakash Agarwal, Equity Analyst, CIMB has a hold rating on Ranbaxy with target price of Rs 630/share.
In an interview to CNBC-TV18 Prakash Agarwal, Equity Analyst, CIMB shared his views on Ranbaxy's Q2FY15 earnings.
The pharma giant turned profitable in the second quarter of current financial year . It reported consolidated net profit of Rs 478 crore during the quarter as against loss of Rs 454 crore in the year-ago period. Its consolidated revenue grew by 16.3 percent to Rs 3,260 crore in the quarter ended September 2014 compared to Rs 2,802 crore in same quarter last year.
Transcript to follow shortly
Anda sedang membaca artikel tentang
US core business continues to be a drag for Ranbaxy: CIMB
Dengan url
https://segarsaries.blogspot.com/2014/10/us-core-business-continues-to-be-drag.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
US core business continues to be a drag for Ranbaxy: CIMB
namun jangan lupa untuk meletakkan link
US core business continues to be a drag for Ranbaxy: CIMB
sebagai sumbernya
0 komentar:
Posting Komentar